Redirecting to https://www.businesswire.com/news/home/20250530679531/en/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-in-Patients-with-EGFR-Mutant-Non-Small-Cell-Lung-Cancer-after-EGFR-TKI-Therapy-in-Global-Study